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H I G H L I G H T S
• Critical parameters for the manual radiosynthesis of Al[18F]PSMA-11 were optimized.
• Large scale automated radiosynthesis of Al[18F]PSMA-11: up to 30 GBq/batch.
• Shelf life stability was determined in various conditions.
• Quality of the end product conforms to Ph. Eur. Guidelines.







A B S T R A C T
Objectives: We report a reproducible automated radiosynthesis for large scale batch production of clinical grade
Al[18F]PSMA-11.
Methods: A SynthraFCHOL module was optimized to synthesize Al[18F]PSMA-11 by Al[18F]-chelation. Results
Al[18F]PSMA-11 was synthesized within 35 min in a yield of 21±3% (24.0± 6.0 GBq) and a radiochemical
purity> 95%. Batches were stable for 4 h and conform the European Pharmacopeia guidelines.
Conclusions: The automated synthesis of Al[18F]PSMA-11 allows for large scale production and distribution of Al
[18F]PSMA-11.
1. Introduction
Among men, prostate cancer (PCa) is the tumor with the second
highest incidence rate in the world (15.0% of all reported cases) with an
estimated 4 million men suffering from PCa according to the World
Health Organisation (Stewart and Wild, 2014). An important problem
in the clinical management is the development of tumor recurrence
after prostatectomy or external beam radiation therapy with curative
intent. One of the key issues herein is the early detection of recurrent
disease (Aus et al., 2005).
In this context, innovative imaging methods have been developed
aimed at the prostate specific membrane antigen (PSMA), a cell surface
protein that is significantly overexpressed in PCa cells, as compared to
other PSMA-expressing tissues (Hillier et al., 2009; Eder et al., 2012;
Schäfer et al., 2012; Bander, 2006; Liu et al., 1997; Sweat et al., 1998;
Mannweiler et al., 2009). Although PSMA is expressed in healthy
prostate tissue too, it was shown that the expression strongly increases
from benign epithelium to malignant neoplasia. Amongst the methods
available to image PSMA-expressing tumors, the recently developed
radiotracer Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)] (68Ga-PSMA-
11) as a 68Ga-labeled PSMA-targeted radioligand became well-estab-
lished across many countries (Maurer et al., 2016).
Unfortunately, 68Ga-labeled compounds are produced with in-house
generators that provide limited activity per synthesis. Thus, depending
on the lifespan of the generator, only 1–4 patient doses per elution can
be produced. Each of these elutions requires a separate synthesis at
different times of the day. Moreover, the short half-life of 68Ga (68 min)
makes transport for long distances not feasible, so that expensive 68Ga
generators must be therefore installed in the local PET centers. While
68Ga-based tracers are still highly valuable in centers without access to
an on-site cyclotron or commercial radiofluoride, sites that do have this
option can reduce costs by replacing 68Ga-based tracers with 18F-based
tracers.
In addition, the physical properties of 68Ga are not favorable.
Sanchez-Crespo (2013). First of all, the short half-life limits the time of
scanning to maximum 2 h post-injection, whereas 18F imaging is pos-
sible up to 4 h post-injection, allowing for better image contrast. The
lower positron yield compared to 18F decreases the sensitivity and the
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high partial volume effect renders the quantification of 68Ga PET scans
more inaccurate compared to 18F. Finally, the higher energy of the
positron reduces the spatial resolution for 68Ga, which is particularly
problematic for the detection of small recurrent tumor lesions with
limited expression of PSMA (Sanchez-Crespo, 2013).
In contrast to 68Ga, large amounts of [18F]fluoride (typically about
150 GBq) can be provided for radiosynthesis in one cyclotron produc-
tion and therefore several attempts have been made to introduce a
suitable 18F-labeled tracer into hospital routine. Tracers such as 18F-
DCFBC (Rowe et al., 2015), 18F-DCFPyl (Wondergema et al., 2017) and
more recently 18F-PSMA-1007 (Cardinale et al., 2017) have shown
great promise but either feature complex low yielding radiosynthesis,
involve precursors with limited availability or are yet to be character-
ized clinically.
An elegant new approach that recently has gained a lot of attention
is the labelling of biomolecules through Al[18F]-chelation. In this
method, 18F- is firmly bound to Al3+ (> 670 kJ/mol) to form an alu-
minum fluoride moiety which can be chelated by a suitable chelator
(Price and Orvig, 2014). When this chelator is attached to a suitable
biomolecule, radiolabelling of a wide variety of complex compounds
becomes possible (Price and Orvig, 2014).
McBride and his coworkers were the first to explore this strategy
and as a proof of principle they radiolabelled a peptide with Al[18F]
using diethylene triaminepentaacetic acid (DTPA) as the chelator
(McBride et al., 2009). Despite promising radiochemical yields using a
low amount of DTPA-peptide, the formed complexes were not suffi-
ciently stable for in vivo applications (D’Souza et al., 2011). This
finding triggered the search for more suitable chelators and both the
pentadentate ligand 1,4,7-triazacyclononane-1,4-diacetate (NODA) and
the hexadentate ligand 1,4,7-triazacyclononane-1,4,7-triacetic acid
(NOTA) were found to form stable complexes with Al[18F]. However,
the need for elevated temperatures (100–120 °C) limits their wide-
spread use (McBride et al., 2010).
Meanwhile, the hexadentate ligand N, N-bis(2-hydroxybenzyl)
ethylenediamine-N,N-diacetic acid (HBED) gained increased attention
as it showed interesting properties towards Al[18F]-based radiolabelling
due to its fast chelating kinetics at room temperature and its favorable
stability constant (24.8) with aluminum (Yokel and Kostenbauder,
1987). Indeed, Malik et al. (2015) and Boschi et al. (2016) successfully
labeled Glu-NH-CO-NH-Lys-(Ahx)-HBED-CC (PSMA-11) with 18F at
room temperature in less than 15 min, leading to Glu-NH-CO-NH-Lys-
(Ahx)-[ Al[18F] (HBED-CC)] (or Al[18F]PSMA-11), hereby succeeding in
combining the optimal PET isotope with a proven pharmacophore for
PSMA-imaging.
However, despite the existence of successful manual labelling pro-
tocols, not a single method has so far been reported to produce large
amounts of clinical grade Al[18F]PSMA-11. The aim of this work is to
establish an automated radiosynthesis procedure, using a commercially
available radiosynthesis platform (Synthra) and readily available re-
agents that would allow widespread use Al[18F]PSMA-11.
2. Materials and methods
2.1. General
All chemicals were purchased from Sigma-Aldrich (Bornem,
Belgium) unless stated otherwise. The precursor, Glu-urea-Lys (Ahx)-
HBED-CC (PSMA-11), was purchased from ABX (Radeberg, Germany).
AlCl3·6H2O, sodium acetate trihydrate, and acetic acid were all trace
metal analysis grade. HPLC eluents, water, acetonitrile, and tri-
fluoroacetic acid (TFA) were of high-grade purity and Ethanol was of
Ph. Eur. quality, unless stated otherwise. Ultrapure water was prepared
using a Seralpur pro 90 CN system (Belgolabo, Overijse, Belgium).
Water for injections (WFI) was obtained from B. Braun Medical N.V.
(Diegem, Belgium).
Sep-Pak Accell Plus QMA, Oasis HLB (360 mg) Oasis WCX (360 mg)
and Sep-Pak C18-Light cartridges were purchased from Waters (Zellik,
Belgium). Alltech Maxi Clean C-18 (300 and 900 mg), Alltech Maxi
Clean C18-HC (300 mg) and Alltech Maxi Clean Prevail C18 (900 mg)
SPE columns were obtained from Achrom (Machelen, Belgium).
Sodium acetate/acetic acid buffers in concentrations of 0.5 M or
0.05 M with a pH of 4.5 were prepared starting from the 0.5 M or
0.05 M solutions of each component and mixed in suitable ratios to
obtain the desired final pH. A phosphate buffer (5 mM, pH 7) was
prepared in a similar way starting from sodium phosphate in mono- and
dibasic form. PSMA-11 was dissolved in water for injections at a con-
centration of 1 mg/500 µL and aliquots of 100 µL were stored frozen at
−18 °C. A solution of 0.01 M AlCl3·6H2O was prepared in a 0.05 M
acetate buffer of pH 4.5 and stored at 4 °C. Isotonic saline was pur-
chased from GE Healthcare (Diegem, Belgium).
Aqueous (aq.) [18F]fluoride was produced by an 18O (p,n) 18F nu-
clear reaction with a Cyclone 18/9 cyclotron (IBA, Ghent, Belgium).
The enriched [180]water (97%) for irradiation was obtained from
Cambridge Isotope Laboratories (Tewksbury MA, USA). Finally, radio-
activity measurements were performed using an Atomlab 100 Plus dose
calibrator (Biodex, New York, United States).
2.2. Manual radiosynthesis
2.2.1. General
The papers of Malik et al. (2015) and Boschi et al. (2016) already
provide the necessary details for a reliable, yet small scale manual
procedure for the radiosynthesis of Al[18F]PSMA-11 and is therefore
used as the basis for the optimization of the automated radiochemical
procedure. However, several parameters needed further attention prior
to upscaling on an automated radiosynthesis platform (Synthra) due to
the restrictions that these modules impose with regard to materials,
volumes, fractionation etc. The optimal procedure, as described by
Boschi was used as a reference and parameters were altered as de-
scribed below (Boschi et al., 2016).
2.2.2. Optimization of reaction parameters
2.2.2.1. Isolation of [18F]fluoride. For these optimization experiments,
freshly produced [18F]fluoride (approximately 2 GBq in 1250 µL of
enriched water) was diluted to 12.5 mL with ultrapure water. Samples
of 1.250 mL of this dilution were eluted over QMA light columns that
were previously preconditioned with 10 mL of an electrolyte (0.5 M
solutions of either NaHCO3, NaNO3, NaCl or NaOAc) and subsequently
flushed with 10 mL WFI. After trapping of the activity, the QMA light
columns were purged to dryness and eluted with each of the
aforementioned electrolytes. The eluate was collected in 200 µL
fractions and the activity of each fraction and the remaining activity
on the QMA column was measured in a dose Calibrator.
2.2.2.2. Formation of the Al-F complex. The formation of the {Al18F}2+
complex was optimized with regard to the added amount of Al3+ and
reaction time. For these experiments, a QMA was first conditioned with
10 mL of 0.5 M NaOAc and rinsed with 10 mL of WFI. Freshly produced
[18F]fluoride was then trapped on the QMA column. To study the effect
of the washing step, the QMA light columns were either flushed with
10 mL of WFI or used without this washing step. The activity was
recovered from the column using 0.6 mL of an acetate buffer (0.5 M) of
pH 4.5 and 100 µL of this eluate was then diluted in 500 µL of 0.5 M
acetate buffer of pH 4.5. Then, an amount of 0, 1, 3, 5, 7, 10 or 25 µL of
an AlCl3 solution (0.01 M in 0.05 M acetate buffer of pH 4.5) was added
and samples were incubated 10 min at room temperature under gentle
shaking. In order to study the time dependency, the experiment was
repeated with 10 µL of ALCl3 solution and samples were taken at fixed
time points (0.5, 1, 2, 5, 10 and 15 min) to monitor the progress of the
complexation reaction. To verify the complexation yields, 5 µL of the
reaction mixture was spotted on an a cation exchanger (a
preconditioned Oasis WCX column, see earlier). The WCX columns
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were then eluted three times with 10 mL of WFI and purged to dryness.
The activity on the columns and in the combined water phase was
measured in a dose calibrator and the yield was calculated as the
percentage of activity on the column relative to the total activity. An
amount of 5 µL of freshly eluted [18F]fluoride was used as a negative
control to correct for non-specific binding of fluoride to the columns.
2.2.2.3. Optimization of the chelation reaction. Freshly produced [18F]
fluoride was trapped on a preconditioned QMA light (Waters) and
eluted with 2 mL of electrolyte in a bulk vial. An amount of 25 μg
precursor (12.5 µL of the stock solution), 3 µL AlCl3 solution (0.01 M in
0.05 M acetate buffer of pH 4.5), 370–740 MBq Na18F (100 µL taken
from the bulk vial), and 150 µL ethanol were mixed and incubated for
10 min at room temperature on a shaking plate. The raw Al[18F]PSMA-
11 was trapped on a C18 Sep-Pak light which was then eluted with
0.5 mL ethanol and diluted with 4.5 mL phosphate buffer (2 mM, pH 7).
For the optimization of the pH, all parameters were kept the same while
the pH of the acetate buffer was varied (either 3.5, 4, 4.5, 5 or 5.5). The
experiment was repeated in the absence of ethanol where this solvent
was replaced by an equal amount of WFI. In a next experiment, the
influence of the relative amount of ethanol to the reaction mixture was
studied by varying the volume of added ethanol: either 0, 60, 120, 150
or 200 µL, resulting in ethanol percentages of 0%, 34%, 51%, 57% and
63% (V%). The influence of the molar Al3+/peptide ratio was
determined by applying the starting conditions and only varying the
amount of added Al3+ to the reaction mixture, either 0.7, 13, 2.0, 2.6,
3.3 and 5.2 µL, resulting in molar Al3+/peptide ratios of respectively:
0.25, 0.5, 0.75, 1, 1.25.
A final experiment involved the optimization of the added amount
of precursor in an upscaled reaction. An amount of 0.6 mL [18F]fluoride
in acetate buffer (0.05 M, pH 4.5) was added to 15 µL of 0.01 M AlCl3 in
0.05 M acetate buffer of pH 4.5 and reacted for 5 min at room tem-
perature. Then 150 µL of PSMA-11 solution (containing either 50, 100,
150 or 200 µg of PSMA-11) and 700 µL EtOH were added and the re-
sulting mixture was allowed to react for 10 min. For all experiments the
yields were calculated based on radio-TLC, as described in the quality
control section.
2.2.2.4. Purification and formulation. For the purification of the crude
reaction mixture, an SPE technique was developed based on the one
described by Boschi et al. (2016). To this end following SPE phases
were tested: Oasis HLB (360 mg), Sep-Pak C18-Light, Maxi Clean C-18
(300 and 900 mg), Maxi Clean C18-HC (300 mg) and Maxi Clean
Prevail C18 (900 mg). All SPE columns were preconditioned using
10 mL of 96% Ethanol, followed by 10 mL of WFI, after which they
were purged to dryness.
First, the labelling was performed according to previous paragraph
and the radiochemical purity was determined by TLC. To simulate the
reaction mixture with minimal activity, 10 µL of the crude reaction
mixture was transferred into a recipient and 765 µL of buffer (0.5 M
acetate buffer of pH 4.5) was added, followed by 700 µL of 96%
ethanol. After homogenisation, the solution was slowly loaded (drop
wise) on each of the SPE phases, which were then purged to dryness.
Alternatively, 10 µL of the crude reaction mixture was transferred into a
recipient to which 765 µL of buffer (0.5 M acetate buffer of pH 4.5),
700 µL of 96% ethanol and 8 mL WFI were added. After homogenisa-
tion, the solution was loaded drop wise on each of the SPE phases,
which were then purged to dryness. Finally, the second experiment was
repeated for the optimal SPE phase with the addition of a washing step
consisting of 10 mL of NaCl an 10 mL of WFI to remove traces of un-
bound fluoride as much as possible.
The activity in the eluate and on the SPE columns was measured
using a dose calibrator. The trapped activity was then compared to the
expected activity, based on the chemical purity. Additionally, the
radiochemical composition of the eluate was determined by TLC.
The recovery of trapped Al[18F]PSMA-11 from the SPE column was
assessed by elution with EtOH/WFI 66/34 (V/V) or with 66% EtOH/
0.01 M phosphate buffer pH 7(V/V). After recovery, the eluate was
diluted to 20 mL to obtain an ethanol concentration of 10%. The so-
lutions for dilution are described below.
2.2.2.5. Shelf life stability testing. The stability of purified Al[18F]PSMA-
11 was studied as a function of time in various storage conditions. The
reaction was performed using 0.6 mL of [18F]fluoride in acetate buffer
(0.05 M, pH 4.5), 15 µL of 0.01 M AlCl3 in 0.05 M acetate buffer of pH
4.5, 150 µL of PSMA-11 solution (containing 150 µg of PSMA-11) and
700 µL EtOH. The mixture was diluted with 8 mL of WFI and sent over
an Oasis HLB (360 mg). The Al[18F]PSMA-11 was the eluted with 2 mL
of 96% Ethanol from the SPE column and subsequently diluted with
18 mL of either 5 mM Phosphate buffer (pH 7.0), 0.9% NaCl, WFI or
67% EtOH in water. All samples were stored at room temperature or at
5 °C (only the phosphate buffered formulation). At regular time points a
2 µL sample was taken for TLC analysis. Additionally, the loss of the
radiolabel after 1 h incubation at room temperature in a 5 mM
phosphate buffer of pH 7.0 was studied in function of the
concentration of PSMA-11 present.
2.3. Automated radiosynthesis
The automated radiosynthesis of Al[18F]PSMA-11 was performed as
a two-step one-pot reaction in a modified SynthraFCHOL synthesis
module (Synthra GmbH, Hamburg, Germany) of which the set-up of the
module is shown in Fig. 1. Optimized parameters from the manual
optimization were programmed into the software and further adjust-
ments to the chemistry, plumbing and programming were made to
further optimize the process to allow for GMP-compliant radio-
synthesis. In order to be as clear as possible, we describe the optimal
configuration and radiosynthesis of Al[18F]PSMA-11 and will then
discuss the optimization process.
First of all, the plumbing was made according to Fig. 1, using the
standard PTFE tubing (ID of 0.8 mm) that is used in the SynthraFCHOL
synthesis module. However, to maximally reduce the flow without the
need to insert an additional flow controller, PEEK tubing with an in-
ternal diameter of 0.12 mm was used for the connections between re-
agent vial A2 and valve V3 (30 cm long), between valve 13 and valve
15 (50 cm long) and finally between valve 17 and valve 8 (10 cm long).
The target of our cyclotron was connected to our module using PTFE
tubing with an ID of 0.8 mm and the outlet of the module is connected
to our dispensing unit by means of PTFE tubing with an ID of 1.0 mm.
Prior to irradiation, the cyclotron target and transfer lines, including
Fig. 1. Schematic representation of the plumbing of the SynthraFCHOL unit for the
radiosynthesis of Al[18F]PSMA-11.
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the module's internal tubing between V23 and the [18O]H2O recovery
vial are flushed with 500 µL of [18O]H2O and purged with Helium. This
rinsing step minimizes possible accumulation of impurities originating
from an earlier productions. After irradiation, the irradiated [18O]H2O
(typically between 80 and 100 GBq) is delivered to the synthesis
module and the [18F]fluoride is trapped on an anion exchange cartridge
(QMA-light, Waters), which is pre-activated with 0.5 M NaOAc (10 mL)
and water (10 mL). The QMA is then washed with 25 mL WFI from A1
to the recovery vial. The [18F]fluoride is then eluted with 0.6 mL
acetate buffer (0.05 M, pH 4.5) into the reactor which is preloaded with
10 µL of 0.01 M AlCl3 in 0.05 M acetate buffer of pH 4.5. The reactor is
closed and the mixture is allowed to react for 5 min at room tempera-
ture, after which the precursor solution, a mixture of 150 µL PSMA-11
(containing 200 µg of precursor) and 700 µL EtOH, is added to the re-
actor via valve 14. All valves are closed again and the reaction mixture
is allowed to react for 10 min at room temperature. When the labelling
is complete, the reaction mixture is diluted with 8 mL WFI and passed
over two Oasis HLB mini-columns in tandem, hereby trapping the Al
[18F]PSMA-11. Subsequently, the trapped product is then washed with
10 mL 0.9% NaCl and 10 mL WFI and then purged to dryness. The
product is then eluted from the mini-column into the bulk vial (pre-
loaded with 20 mL of 5 mM phosphate buffer of pH 7.0) in the dis-
pensing hotcell with 3 mL of EtOH/phosphate buffer (5 mM, pH 7.0)
67/33 (v/v). After completion of the transfer, the lines are purged with
4 mL of phosphate buffer (5 mM, pH 7.0). After homogenisation by
manual shaking, the formulation is ready for dispensing and use.
An important side note with regard to the set-up of the synthesis
module is related to the recovery of the enriched water. In order to
reduce costs, an extra valve may be installed between V11 and the
recovery vial. This will allow to isolate the enriched water which can be
submitted for reprocessing.
2.4. Quality control
Radiochemical purity and activity/peptide ratio (total activity in
MBq divided by the total amount of peptide in mmoles) of Al[18F]
PSMA-11 were determined by analytical high-performance liquid
chromatography (HPLC) using an Agilent 1260 infinity system (Agilent
Technologies, Diegem, Belgium) consisting of a quaternary pump, an
auto-sampler and a column oven. Ultraviolet (UV) absorption was de-
tected with an Agilent 1260 variable wavelength detector at a wave-
length of 220 nm in series with a Raytest “Gabi Star” detector (Elysia-
Raytest, Liège, Belgium) for radioactivity detection. As stationary phase
a Prevail C18 (4.6 × 250 mm, 5 µ, Lokeren, Belgium) was used at
40 °C. As mobile phase a gradient system (Solvent A: water (0.1%) TFA;
Solvent B: acetonitrile (0.1% TFA); between 0 and 4 min: 15% B, be-
tween 4 and 11 min: from 15% B to 70%, between 11 and 14 min from
70% B to 15% B and between 14 and 16 min: 15% B) was used with a
flow rate of 2 mL/min. The radiochemical purity was also determined
by TLC using Alugram RP18-W/UV254 plates (Machery Nagel, Düren,
Germany) and 70% acetonitrile in water as mobile phase and a Raytest
MiniGitaTLC scanner for detection of the radioactive spots. Endotoxins
were determined using the Endosafe PTS system (Charles-River,
Charleston, USA). Residual aluminum was determined using the Tec-
Control Breakthru Kit (Biodex, Groningen, The Netherlands). The pH of
al final formulations was checked using Paper dosatest pH 4.5–10.0
strips (VWR-international, Oud-Heverlee, Belgium).
3. Results and discussion
3.1. Manual radiosynthesis of Al[18F]PSMA-11
For the manual radiosynthesis we used the work of Malik and Boshi
as a reference and then optimized and upscaled individual parameters
to fit the needs of our automated system (Malik et al., 2015; Boschi
et al., 2016). Each essential reaction step and parameter is sequentially
discussed below.
3.1.1. Isolation of [18F]fluoride
In previous work, the radiofluorine that is coming from the QMA
during elution is fractionated (typically 100 µL/fraction) after which
the most active fraction is identified and then used for radiolabelling
(Malik et al., 2015; Boschi et al., 2016). This accomplishes two things:
firstly, the radiofluorine is recovered in the highest possible activity per
volume and the bulk of impurities (metal ions) that elute with the
solvent front are avoided. This elegant method plays a crucial role in
achieving the high yields that are associated with the manual procedure
but is hard to implement in an automated module. In an effort to
translate this strategy to an automated procedure, several different
approaches were tried including the use of dilute electrolyte solutions
and gradient elutions. However, these strategies were found to be too
impractical (i.e. large elution volumes) or lead to highly variable re-
sults, hampering the reproducibility of the method. Therefore, to keep
the method as simple as possible, we aimed to develop a straightfor-
ward elution method, using an appropriate volume of the most suitable
electrolyte for subsequent radiolabelling, without the need of fractio-
nation.
First the retention of radiofluorine was studied on QMA light col-
umns that were preconditioned with different electrolytes (NaHCO3,
NaNO3, NaCl or NaOAc). In all cases, radiofluorine was trapped with an
efficiency exceeding 99.9%. However, different elution patterns were
observed when the same electrolytes were used to displace the radio-
fluorine from the anion exchanger (shown in Fig. 2). From this graph it
becomes clear that, with regard to a fractionated approach, 0.9% NaCl
obviously is the electrolyte of choice as the first 200 µL can be discarded
and the bulk of the activity can be recovered in the second fraction of
200 µL. However, the recovery of radiofluorine from the QMA column
is nearly quantitative for all electrolytes when a total unfractionated
elution volume of 600 µL is used. When these solutions were then used
for subsequent radiolabelling (shown in Table 1), the acetate buffer of
pH 4.5 showed the best radiochemical yield and was therefore retained
for further optimization.
Next, the wash step following the trapping of the radiofluorine was
optimized. Low, irreproducible yields were observed when the column
was not flushed with WFI. Slightly better, but highly variable yields
were obtained when the QMA was flushed with 10 mL of WFI.
However, when we used 25 mL of WFI, labelling yields remained con-
stant and these did not improve by increasing the amount of WFI for
washing.
Based on aforementioned observations, we propose a QMA light
that is preconditioned with 10 mL of 0.5 M acetate buffer and rinsed
with 10 mL WFI prior to use. After trapping of the freshly irradiated
fluorine (about 100 GBq in 2000 µL), the QMA should be rinsed with
25 mL of WFI and purged to dryness using a Helium flow. The
Fig. 2. Elution patterns of [18F]fluoride from a QMA-light, using 0.5 M solutions of either
NaHCO3, NaNO3, NaCl or NaOAc in WFI. The recovery of the trapped radioactivity, ex-
pressed as the % of the total activity (n = 5) is plotted as a function of the elution volume.
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radiofluorine can then be eluted almost quantitatively with 600 µL of
0.5 M acetate buffer pH 4.5.
3.1.2. Formation of the Al-F complex
The key step in the radiolabelling of PSMA-11 is the formation of
the complex between aluminum and fluoride leading to the aluminum
fluoride moiety where 18F- is firmly bound to Al3+ (> 670 kJ/mol).
Literature suggests that when fluoride is present in low concentrations
relative to Al3+, mainly monofluoride species ({AlF}2+) are formed
and as the concentration of fluoride increases, a series of AlFn3−n
species can be observed, where n ranges from one to six (Price and
Orvig, 2014). However, it is only the {AlF}2+ species that can be effi-
ciently chelated by the HBED chelator (Price and Orvig, 2014).
Therefore we optimized the required amount of Al3+ and defined the
minimal time that is required to form the Al-F complex. These data are
summarized in Fig. 3. From these data it becomes clear that up from 70
nanomoles of Al3+ no additional benefit is observed with regard to the
amount of {Al18F}2+ that can be formed. When the formation of
{Al18F}2+ is compared between “clean” QMA columns (washed with
25 mL WFI after trapping of the radiofluoride) or “dirty” ones (eluted
right after trapping), the influence of the wash step becomes clear:
{Al18F}2+ formation is 9% higher when a wash step is included. When
the yield of the complex formation is plotted as a function of time, it
becomes clear that a plateau is reached after 2 min. In order to reduce
the effects due to timing and pipetting errors, an amount of 100 nmol
and an incubation time of 5 min was used for future experiments.
3.1.3. Optimization of the chelation reaction
Aluminum forms octahedral complexes, requiring hexadentate li-
gands for optimal binding (Malati, 1999). However, as we use the HBED
chelator of PSMA-11, which is also used for the complexation of Gal-
lium-68, one dentate will be free as the fluoride occupies the sixth
position of the complex (McBride et al., 2009; D’Souza et al., 2011). For
radiolabelling this poses no problem, as was proven in earlier work
(Malik et al., 2015; Boschi et al., 2016). This will, however, have an
effect on the stability of the final complex which will be discussed
below. As was proven before, the chelation process depends on pH,
(relative amounts) of reagents, temperature and the type and amount of
co-solvent that is used in the complexation reaction. Moreover, as has
been alluded before, metallic impurities coming from the target should
also be considered. Last but not least, the order in which reagents are
added to the reactor is also taken into account as an automated pro-
cedure is limited by restrictions inherent to an automated module.
As is clear from Fig. 4, the optimal pH for the chelation process is
4.5, which is consistent with previous reports. In this context it is im-
portant to point out that the choice of electrolyte for the elution of the
QMA column plays an important role as it might substantially change
the pH of the final mixture, especially since it represents roughly 50%
of the total volume. Moreover, when too dilute acetate buffers are used,
a slight shift in pH can be observed due to the addition of the reagents.
Therefore we opted to elute the activity with 600 µL of an acetate buffer
of pH 4.5 with a buffer concentration of 0.05 M.
Secondly we studied the effect of the amount of co-solvent on the
Table 1
Summary of the QC tests and results for the validation runs (n = 3) of the automated radiosynthesis of Al[18F]PSMA-11. (Starting activity± 100 GBq).
Measured parameter Method/Equipement Validation approach Results (N = 3)
Activity Dose calibrator Methodology for validation and control testing of dose calibrators is based on the IAEA
guidelines for nuclear medicine instruments.
24.0± 6.0 GBq
Appearance Visual inspection Visual inspection of the content of the vial as described in Ph. Int. methods of analysis
chapter as applied to radiopharmaceuticals.
Conform
Acidity/Alkalinity pH paper Direct pH measurement based on colour indicator. 7.0±0.1
Identity HPLC with UV and
radioactivity detection
Identification of the radioactive compound by HPLC using co-elution technique.
Retention times between radioactive product and reference standard are compared.
Detection by UV-spectrometry at 220 nm and radioactivity detection.
Conform
Radiochemical purity by TLC TLC - radiodetection Reversed Phase TLC eluted with AcN/Water 70/30 solution. Separation of fluoride and




HPLC with UV and
radiodetection
Method based on methodology developed by Malik et al. Validation according to ICH
guidelines for analytical procedures as applied to testing for impurities. Validation





Chemical purity: Aluminum Colorimetry Method based on the Aluminum breakthrough kit (Biodex) <20 µg/V
Radionuclidic identity and
purity: half-life
Dose calibrator Methodology as described in Ph. Eur. as applied to short-lived radiopharmaceuticals. 111.3± 2.8
Radionuclidic identity and
purity: Eγ
Gamma-spectrometry Methodology as described in Ph. Eur. as applied to short-lived radiopharmaceuticals. 512.9± 4.0 keV
Radio-nuclidic purity (long
lived impurities)
Gamma-spectrometry Methodology as described in Ph. Eur. as applied to short-lived radiopharmaceuticals. < 0.1%
Bacterial endotoxins LAL-test Method with reference to Ph. Eur. 2.6.14. < 10 EU/V
Sterility Membrane filtration Method with reference to Ph. Eur. 2.6.1. Sterile
Fig. 3. Complexation yields (n = 3) after 5 min of incubation at room temperature as a
function of the added amount of Al3+ for untreated [18F]fluoride (upper graph).
Complexation yields (n = 1) as a function of time for washed and untreated [18F]fluoride
(lower graph) using 20 µL of.
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reaction mixture. We only studied the yield as a function of the amount
of ethanol due to its compatibility with human applications. A marked
increase in labelling yield can be observed with increasing ethanol
concentrations but at about 50% a plateau is reached. In order to fa-
cilitate the preconcentration step we aimed to keep the amount of
ethanol to a minimum and opted to add 600 µL to the reaction mixture,
resulting in a 48.6% ethanol in water (v%) concentration.
From Fig. 5 it becomes apparent that the labelling yield increases
with the amount of precursor added, as can be expected. However,
while it is tempting to use more precursor to force the reaction to even
higher yields and to minimize the effect of competing metallic im-
purities coming from the cyclotron, it should be noted that this comes at
a drastic increase in cost due to the expensive precursor. Moreover, as
micro-dosing is preferred for radiotracers with regard to safety and
regulatory issues, it is advisable to keep concentrations to a strict
minimum. We opted to apply a maximum of 200 µg PSMA-11 for each
synthesis as in our experience this provides a sufficient good yield and
an excellent reproducibility. When we lowered the amount of precursor
to 150 µg we sometimes experienced reduced yields (up to 30% less),
which are most likely due to fluctuating amounts of metallic impurities
originating from the target material.
The last parameter to be considered is the relative amount of Al3+
that is added to the reaction mixture. The optimization of this para-
meter is shown in Fig. 6. When the molar Al3+/peptide ratio drops
below 0.5, an apparent plateau is reached, which is in line with the
findings of Cleeren et. al. on the very similar RESCA1 chelator
(Pillarsetty et al., 2016; Charlot, 1983). Based on these observations
and the results from preceding formation of the Al-F complex, we
propose a ratio of 0.5 (amounting to 100 nanomoles of Al3+ for a re-
action with 200 µg of PSMA-11) for maximum yields and reproduci-
bility.
An important side note is related to the quality and shelf-life of the
used precursor. We noticed that after 6 months, the labelling yield was
cut to half as compared to a fresh batch of precursor. Concomitantly,
during QC HPLC analysis, a reduced chemical purity can be observed
when old precursor was used for the radiosynthesis (data not shown).
Keeping a large stock of precursor in the freezer is hence not re-
commended. Finally, it is also recommended to use GMP-grade PSMA-
11 (from ABX, Radeberg, Germany) for the automated radiosynthesis as
it results in a higher radiochemical purity of the final preparation. This
is due to the presence of an unidentified additional peak on the HPLC
radiochromatogram when non-GMP grade PSMA-11 was used for
radiolabelling, as is clear from the selected chromatograms shown in
Fig. 7.
3.1.4. Purification and formulation
The next important step is the purification of the reaction mixture.
We opted to adapt the earlier described preconcentration technique
(Boschi et al., 2016) as it is a simple and fast method. However, some
changes were required as straightforward application of the protocol
lead to loss of product-activity up to 50% for all tested SPE columns.
These losses are related to the increase in reaction volume leading to a
mismatch with the stationary phase. We opted to dilute the mixture
with 8 mL WFI prior to concentration, leading to a final ethanol
Fig. 4. Labelling yields (n = 1) of Al[18F]PSMA-11 as a function of pH. Reactions were
performed as described under Section 2.2 and only the pH of the Acetate buffer was
varied. In a second experiment (blue line) EtOH was replaced by 150 µL water and the pH
of the Acetate buffer was varied (Upper Graph). The lower graph shows the labelling yield
as a function of the relative amount of ethanol in the reaction mixture (in V%) for re-
actions were performed as described under Section 2.2 with the added volume of EtOH as
the only variable.
Fig. 5. Manual labelling yields (relative to the total amount of activity added, n = 3) as a
function of added amount of precursor. Reaction parameters: 0.6 mL [18F]fluoride in
acetate buffer (0.05 M, pH 4.5) was added to 15 µL of 0.01 M AlCl3 in 0.05 M acetate
buffer of pH 4.5 and reacted for 5 min at room temperature. Then 150 µL of PSMA-11
solution (mass was varied) was added together with 700 µL of EtOH and the mixture was
incubated for 10 min at room temperature.
Fig. 6. Labelling yields (n = 3) as a function of the molar Al3+/peptide ratio. Reactions
were performed as described under Section 2.2, using a fixed amount of precursor while
varying the amount of added Al3+.
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concentration of 7.5% (V%), in order to increase the retention of Al
[18F]PSMA-11 on the stationary phase. Seven different SPE systems
were evaluated for their retention behavior in these conditions. The
Sep-Pak C18 Plus Light, Alltech Maxi Clean C18 (300 mg and 900 mg),
Alltech Maxi Clean HC C18 (300 mg) systems were immediately dis-
carded as more than 30% of product-activity was lost during the pre-
concentration step. The Waters Sep-Pak C18 Plus Short column was also
discarded as breakthrough of Al[18F]PSMA-11 was observed during the
washing step. Only the Oasis HLB and the Alltech Maxi Clean Prevail
C18 (300 mg) showed good retention (> 75% for a single column
and>98% with two columns in tandem) with no significant break-
through of Al[18F]PSMA-11 during the washing step. Finally the ac-
tivity could successfully be recovered (recovery>98%) from both SPE
column systems by elution with 3 mL of EtOH/WFI 66/34 (V/V). Fol-
lowing the stability study this was changed to 3 mL of 66% EtOH/
0.01 M phosphate buffer pH 7(V/V) for reasons discussed below. De-
spite the good trapping efficiency, the Prevail C18 phase was not pre-
ferred due to the observed higher back-pressure and resulting slow flow
rate in our automatic system, as compared to the HLB columns. Hence
we propose two HLB (360 mg) SPE columns in tandem for the pur-
ification of Al[18F]PSMA-11.
3.1.5. Shelf life stability testing
As stated earlier, the free (sixth) dentate of the HBED chelator is a
point of concern as it could compete with [18F]fluoride for binding on
the aluminum ion. Limited data is available on the stability of Al[18F]
PSMA-11 (Malik et al., 2015; Boschi et al., 2016). So far it was accepted
that a radiochemical purity of> 97% was observed in buffered solution
at pH 6.8 in comparison with unbuffered saline formulation, which
showed a roughly 20% decrease in radiochemical purity after 3 h
(Boschi et al., 2016). Our in depth study of the stability is shown in
Fig. 8. These data suggest that the stability is clearly dependent on the
temperature (entropy effect), the type of buffer (which also competes
with the chelator) and the dilution factor of the original formulation.
Buffer systems that include components that feature an important
complexation constants, e.g. citrate (Pk1 = 7.0), with Aluminum should
be avoided (Charlot, 1983). Despite the weak complexation constant of
H2PO4- with Aluminum (pK1 = 2.1) we propose a phosphate buffer of
5 mM at pH 7, with a final formulation volume of maximally 30 mL.
When stored under these conditions at room temperature, the
Fig. 7. Radiochromatograms obtained from the quality control by HPLC of freshly produced Al[18F]PSMA-11 using either the regular PSMA-11 (upper graph) or GMP-quality PSMA-11
precursor from ABX (Radeberg, Germany).
Fig. 8. Stability of Al[18F]PSMA-11 as a function of time in various storage conditions.
(Upper graph). Loss of the radiolabel after 1 h incubation at room temperature in a 5 mM
phosphate buffer of pH 7.0 plotted in function of the concentration of PSMA-11 present
(Lower graph).
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compound was stable (less than 5% loss of label) for at least 4 h. When
the compound is to be distributed to peripheral institutions, we suggest
to keep the stock solution refrigerated as no significant loss of the
radiolabel was observed in these conditions for at least 6 h.
3.2. Automated radiosynthesis
The most important factor in the automatization of the radio-
synthesis is the sequence in which the reagents are added. It may be
tempting to simplify the procedure, hereby reducing the complexity
(and cost) of the synthesis module. The simplest set-up would be to load
the reactor with the precursor- and Al3+ solution, followed by elution
of the radiofluoride into the reactor. However, it was found that this
approach leads to low radiochemical yields and the formation of an
unstable radiolabeled compound which is most likely a diastereoisomer
of the desired compound. A similar phenomenon has already been
observed by McBride et al. (2010) for the chelation of AlF2+ by the
NOTA chelator. The appearance of this diastereoisomer is probably due
to the formation of a HBED-Al3+complex with a different geometry
prior to the addition of the radiofluorine, leading to a different final
complex than when preformed AlF2+ is allowed to react with the HBED
chelator.
Nevertheless, when the radiofluorine is incubated with Al3+ for
5 min prior to addition of the precursor, followed by an additional in-
cubation to bind the Al-F complex to the HBED chelator of the pre-
cursor, the undesired compound is no longer observed and reproducible
high yields of Al[18F]PSMA-11 are obtained. Moreover, all manually
optimized parameters can be applied without further modifications.
The described automated method yields 21±3% (not corrected for
decay) of Al[18F]PSMA-11 within 35 min. This yield is much lower than
observed for the described manual radiosynthesis procedures, which is
probably due to the fact that the automated system does not discard a
fraction of the eluate coming from the QMA. While the rinsing step with
25 mL is thought to remove impurities coming from the target, it is
highly probable that traces persist. Moreover, as the total elution vo-
lume ends up in the reactor, relatively higher levels of metal ions are
suspected to be present in the reactor that can impede the chelation of
AlF2+. Moreover, as metallic sharps are used in the automated system,
as opposed to the manual syntheses, it is not excluded that they also
influence the radiolabelling yield negatively. Despite this consideration,
using the described automated radiosynthesis, we were able to produce
batches up to 30 GBq of Al[18F]PSMA-11, which will allow large scale
application of this tracer.
Quality control parameters of batches produced thus far (meanwhile
more than 50) show that high-quality Al[18F]PSMA-11 can be produced
using the described method. Moreover, the activity/peptide ratio of Al
[18F]PSMA-11 (120± 28 GBq/µmol) is similar to the earlier described
NOTA analogue (McBride et al., 2010) and superior to that of 68Ga-
PSMA-11 (Pillarsetty et al., 2016). Meanwhile our cyclotron site at the
campus of the University Hospital Ghent (Belgium) has acquired GMP-
accreditation for the production of Al[18F]PSMA-11 and the compound
is meanwhile being studied in a large scale prospective clinical trial.
The QC data of the validation runs are shown below in Table 1.
Our final comments are related to the future radiolabeled com-
pounds aimed at PSMA. Interestingly, Cleeren et. al. (2016, 2017) re-
cently developed the more stable RESCA1 chelator for the radiolabel-
ling of biomolecules with AlF2+. This chelator holds great promise for
further improvement of this radiolabelling strategy and PSMA-RESCA1
could replace PSMA-11 as the precursor of choice for the production of
a radiofluorinated PSMA based compound once it has been sufficiently
characterized preclinically and when it becomes freely available. Due to
the similarity between PSMA-RESCA1 and PSMA-11, we expect that the
optimized parameters and set-up of the automated module that are
described in this paper can also be applied for this new chelator, en-
suring a long term applicability of this methodology.
4. Conclusion
The optimized synthesis of Al[18F]PSMA-11 using a SynthraFCHOL
module allows for large scale production of Al[18F]PSMA-11
(21%±3% e.o.s.), suitable for clinical routine. Moreover, this method
can be applied in a GMP setting and is expected to be compatible with
the new chelators that are currently being developed. We expect that
widespread use of this technology will have a beneficial impact on
prostate cancer diagnosis worldwide as large populations of patients
can be processed faster and at a reduced cost, relative to 68Ga-based
radiotracers.
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